In a groundbreaking move, the US Food and Drug Administration (FDA) has granted full approval to Travere Therapeutics’ Filspari (sparsentan) for treating primary IgA nephropathy (IgAN) in adults at risk of disease progression. This decision, announced on September 5, 2024, marks a significant milestone in the battle against this rare kidney disease, offering a new […]
Novartis presented compelling interim results from the Phase III ALIGN study evaluating the efficacy of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN). This data was highlighted at the European Renal Association (ERA) Congress, showcasing a significant 36.1% reduction in proteinuria at 36 weeks compared to placebo, […]
In a major development in the biotechnology industry, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN) have announced a definitive agreement where Vertex will acquire Alpine for $65 per share, amounting to approximately $4.9 billion in cash. This transaction, unanimously approved by both companies’ Boards of Directors, is set to close […]
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around $3.5 billion. The acquisition will bring two late-stage medicines for rare, severe chronic kidney diseases into Novartis’ portfolio. It aligns with Novartis’ strategy to focus on innovative medicines and will […]
Chinook Therapeutics, a US-based biopharma company, has secured orphan drug designation for atrasentan from the European Commission (EC) for the treatment of primary IgA nephropathy (IgAN). The decision from the EC comes after the adoption of a positive opinion by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). Atrasentan has […]
Swedish pharmaceutical company Calliditas Therapeutics has initiated the Phase 3 NEFIGARD trial to evaluate its lead drug candidate, Nefecon, for treating IgA nephropathy (IgAN), commonly known as Berger’s disease. The NEFIGARD trial marks a significant step for Calliditas Therapeutics as it begins enrolling patients for a late-stage study designed to assess the effectiveness of Nefecon […]